International Assets Investment Management LLC boosted its position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 38,432.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 57,414 shares of the company's stock after buying an additional 57,265 shares during the period. International Assets Investment Management LLC owned approximately 0.19% of Medpace worth $19,165,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Fidelis Capital Partners LLC acquired a new position in Medpace in the first quarter valued at $31,000. J.Safra Asset Management Corp lifted its holdings in Medpace by 87.0% in the first quarter. J.Safra Asset Management Corp now owns 101 shares of the company's stock valued at $41,000 after buying an additional 47 shares during the period. DT Investment Partners LLC acquired a new position in Medpace in the second quarter valued at $41,000. Ashton Thomas Private Wealth LLC acquired a new position in Medpace in the second quarter valued at $52,000. Finally, EntryPoint Capital LLC bought a new stake in Medpace in the first quarter valued at $54,000. Institutional investors and hedge funds own 77.98% of the company's stock.
Medpace Stock Down 1.4 %
MEDP stock traded down $4.61 during trading on Wednesday, reaching $325.15. The stock had a trading volume of 80,981 shares, compared to its average volume of 273,515. Medpace Holdings, Inc. has a one year low of $239.00 and a one year high of $459.77. The company's 50 day moving average is $349.01 and its two-hundred day moving average is $380.03. The company has a market capitalization of $10.07 billion, a price-to-earnings ratio of 33.61, a P/E/G ratio of 1.74 and a beta of 1.35.
Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings data on Monday, October 21st. The company reported $3.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.77 by $0.24. Medpace had a net margin of 17.66% and a return on equity of 50.87%. The business had revenue of $533.32 million during the quarter, compared to the consensus estimate of $540.99 million. During the same period in the prior year, the firm posted $2.22 EPS. The firm's quarterly revenue was up 8.3% compared to the same quarter last year. As a group, research analysts predict that Medpace Holdings, Inc. will post 11.77 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several research firms have weighed in on MEDP. TD Cowen decreased their price target on shares of Medpace from $413.00 to $372.00 and set a "buy" rating for the company in a research note on Wednesday, October 23rd. Guggenheim decreased their price target on shares of Medpace from $464.00 to $432.00 and set a "buy" rating for the company in a research note on Wednesday, July 24th. Robert W. Baird downgraded shares of Medpace from an "outperform" rating to a "neutral" rating and decreased their price target for the company from $413.00 to $349.00 in a research note on Wednesday, October 23rd. Baird R W downgraded shares of Medpace from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, October 23rd. Finally, Deutsche Bank Aktiengesellschaft decreased their price target on shares of Medpace from $395.00 to $336.00 and set a "hold" rating for the company in a research note on Wednesday, July 24th. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $380.00.
View Our Latest Stock Report on Medpace
Medpace Company Profile
(
Free Report)
Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
See Also
Before you consider Medpace, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medpace wasn't on the list.
While Medpace currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
